{"id":7872,"date":"2026-09-19T13:00:36","date_gmt":"2026-09-19T13:00:36","guid":{"rendered":"https:\/\/autism.fratnow.com\/blog\/navigating-the-frat-conversation-with-your-physician-2\/"},"modified":"2026-09-19T05:26:12","modified_gmt":"2026-09-19T05:26:12","slug":"who-may-benefit-from-the-frat-test","status":"publish","type":"post","link":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/","title":{"rendered":"Who May Benefit from the FRAT\u00ae Test"},"content":{"rendered":"<p>[vc_row][vc_column][vc_single_image image=&#8221;7873&#8243; img_size=&#8221;full&#8221;][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;The FRAT<sup>\u00ae<\/sup> test is a specialized test.&#8221;][vc_column_text single_style=&#8221;&#8221;]FRAT<sup>\u00ae<\/sup> serves as a biomarker test designed to identify a very specific immune-mediated problem \u2014 folate receptor alpha autoantibodies that can block the transport of folate into the brain, even when blood folate levels appear perfectly normal. The individuals most likely to benefit are those with clinical presentations consistent with &#8220;<a href=\"https:\/\/autism.fratnow.com\/blog\/cerebral-folate-deficiency-an-overview\/\">cerebral folate deficiency<\/a>&#8221; despite normal serum folate, and those for whom identifying this mechanism could meaningfully alter treatment decisions.[\/vc_column_text][vc_custom_heading text=&#8221;What Exactly Does FRAT<sup>\u00ae<\/sup> Measure?&#8221; el_id=&#8221;blog-scroll-point-1&#8243;][vc_column_text single_style=&#8221;&#8221;] The <a href=\"https:\/\/www.fratnow.com\/order-a-test-kit.php\"><strong>FRAT<sup>\u00ae<\/sup> test (Folate Receptor Autoantibody Test)<\/strong><\/a><br \/>\ndetects and quantifies autoantibodies directed against folate receptor alpha (FR\u03b1), a high-affinity membrane protein responsible for transporting 5-methyltetrahydrofolate (5-MTHF) \u2014 the active form of folate \u2014 across the blood-brain barrier and into the cerebrospinal fluid.[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]The test differentiates between two types of autoantibodies:<\/p>\n<ul>\n<li><strong>Blocking antibodies<\/strong>: directly interfere with folate binding to the receptor<\/li>\n<li><strong>Binding antibodies<\/strong>: attach to the receptor without necessarily blocking its function directly.<\/li>\n<\/ul>\n<p>This distinction matters. Blocking antibodies are the ones most clearly implicated in cerebral folate deficiency \u2014 they prevent 5-MTHF from reaching the brain. Binding antibody titers, however, have also been shown to correlate with treatment response in some populations.<\/p>\n<p>Developed by Dr. Edward V. Quadros at SUNY Downstate, FRAT\u00ae is designed as a blood test that can serve as a less invasive screening tool, potentially replacing the need for lumbar puncture as an initial step in evaluation.<\/p>\n<p>[\/vc_column_text][vc_custom_heading text=&#8221;The Core Clinical Entity: Cerebral Folate Deficiency (CFD)&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text single_style=&#8221;&#8221;]Before identifying who should be tested, it helps to understand the condition FRAT<sup>\u00ae<\/sup> is designed to detect.<\/p>\n<p>Cerebral folate deficiency is defined by <strong>low cerebrospinal fluid 5-MTHF despite normal serum folate levels.<\/strong>This paradox \u2014 adequate folate in the blood but insufficient folate in the brain \u2014 is the hallmark of the condition. The symptoms can be devastating: developmental delay, speech impairment, motor dysfunction, seizures, and features overlapping with autism spectrum disorder.<\/p>\n<p>In the landmark 2005 study published in the <em>New England Journal of Medicine<\/em>, Ramaekers and colleagues found that <strong>25 of 28 children (89%) with cerebral folate deficiency had high-affinity blocking folate receptor autoantibodies<\/strong>,while none of the 28 control subjects tested positive. Oral folinic acid normalized CSF 5-MTHF levels and led to clinical improvement.[\/vc_column_text][vc_custom_heading text=&#8221;Who Should Consider FRAT<sup>\u00ae<\/sup> Testing?&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_custom_heading text=&#8221;Group 1: Infants and Young Children with Symptoms of Cerebral Folate Deficiency&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>This is the most well-established population. FRAT\u00ae testing may be warranted in infants and young children presenting with:<\/p>\n<ul>\n<li><strong>Developmental delay<\/strong> (particularly affecting speech, learning, or behavior)<\/li>\n<li><strong>Abnormal muscle tone<\/strong> (hypotonia or ataxia)<\/li>\n<li><strong>Motor dysfunction<\/strong> or movement disorders<\/li>\n<li><strong>Seizures<\/strong> (especially treatment-resistant)<\/li>\n<li><strong>Decelerating head growth<\/strong><\/li>\n<li><strong>Severe sleep disturbances and irritability<\/strong><\/li>\n<\/ul>\n<p>The clinical picture often emerges between <strong>4 and 6 months of age<\/strong>. Early detection matters because folinic acid treatment has been shown to normalize CSF folate levels and produce clinical improvement.<\/p>\n<p>[\/vc_column_text][vc_custom_heading text=&#8221;Group 2: Children with Autism Spectrum Disorder and Neurological Deficits&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>Not every child with ASD needs FRAT<sup>\u00ae<\/sup> testing. But a substantial subgroup may benefit.<\/p>\n<p>Research from Dr. Quadros and collaborators found that <strong>approximately 70% of children with<\/strong> <a href=\"https:\/\/autism.fratnow.com\/blog\/a-comprehensive-introduction-to-autism-spectrum-disorder\/\"><strong>autism spectrum disorder<\/strong><\/a> <strong> tested positive for<\/strong> <a href=\"https:\/\/autism.fratnow.com\/blog\/folate-receptor-autoantibodies-in-families-with-autistic-individuals\/\"><strong>folate receptor autoantibodies<\/strong><\/a><strong>.<\/strong>In a 2008 study of 25 children with early-onset low-functioning autism with or without neurological deficits,<strong>23 of 25 had low CSF 5-MTHF despite normal serum folate<\/strong>, and<br \/>\n<strong>19 of these cases could be explained by serum folate receptor autoantibodies.<\/strong><\/p>\n<p>A 2024 retrospective analysis of 110 ASD patients found that higher binding FRAA titers were associated with greater response to leucovorin (folinic acid) treatment, with improvements in social responsiveness and irritability.<\/p>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p><strong>Signals that might warrant testing in ASD include<\/strong>:<\/p>\n<ul>\n<li><strong>Developmental regression<\/strong> (especially after a period of typical development)<\/li>\n<li><strong>Associated neurological deficits<\/strong> (seizures, movement abnormalities)<\/li>\n<li><strong>Severe gastrointestinal symptoms<\/strong> (some research suggests higher FRAA prevalence in this subgroup)<\/li>\n<li><strong>Limited response to standard nutritional approaches<\/strong><\/li>\n<li><strong>Family history of autoimmune conditions<\/strong><\/li>\n<\/ul>\n<p>A critical caveat: <strong>FRAT is not a diagnostic test for autism<\/strong> and does not replace a comprehensive ASD assessment. It identifies a potentially treatable biological subgroup within a heterogeneous condition.<\/p>\n<p>[\/vc_column_text][vc_custom_heading text=&#8221;Group 3: Women with a History of Neural Tube Defect Pregnancy&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text single_style=&#8221;&#8221;]The FRAT<sup>\u00ae<\/sup> story has deep roots in reproductive medicine.<\/p>\n<p>In 2004, Rothenberg and colleagues published findings in the <em>New England Journal of Medicine<\/em> showing that <strong>9 of 12 women with a current or previous pregnancy affected by neural tube defects had autoantibodies against folate receptors<\/strong>,compared to only 2 of 20 control women. These antibodies blocked folate binding and cellular uptake.<\/p>\n<p>A subsequent study in a Chinese population confirmed a <strong>dose-response relationship<\/strong> between maternal plasma FR autoantibody levels and neural tube defect risk. Women in the highest tertile of IgG autoantibodies had a <strong>5.53-fold increased odds<\/strong> of having an NTD-affected pregnancy.<\/p>\n<p>The clinical implication is significant: some neural tube defects may occur <strong>despite adequate folic acid supplementation<\/strong> because autoantibodies prevent folate from reaching the developing fetus. For women with a history of NTD-affected pregnancy \u2014 or unexplained recurrent pregnancy complications \u2014 FRAA evaluation may provide a previously overlooked explanation.[\/vc_column_text][vc_custom_heading text=&#8221;Group 4: Individuals with Treatment-Resistant Schizophrenia or Related Psychotic Disorders&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>A study of patients with schizophrenia unresponsive to conventional treatment found that <strong>15 of 18 patients (83.3%) had positive serum FR autoantibodies<\/strong>, compared to only 1 in 30 controls (3.3%). Antibody titers fluctuated over time, correlating with CSF folate levels. In seven patients treated with folinic acid for at least six months, <strong>clinical improvement was observed<\/strong>.<\/p>\n<p>The authors recommended that <strong>assessment of FR autoantibodies in serum be considered for schizophrenic patients<\/strong>, particularly those who do not respond adequately to standard treatment.<\/p>\n<p>[\/vc_column_text][vc_custom_heading text=&#8221;Group 5: Individuals with Rett Syndrome and Related Conditions&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text single_style=&#8221;&#8221;]Rett syndrome has been associated with low CSF 5-MTHF in a subset of patients. A European study found that <strong>14 of 33 Rett patients (42%) had low CSF folate levels despite normal plasma folate<\/strong>, and <strong>blocking FR autoantibodies were found in 8 patients (24%)<\/strong>, six of whom had low CSF folate.<\/p>\n<p>The incidence was notably higher in North-Western Europe compared to North America, where food folate fortification may provide protective effects. FRAT<sup>\u00ae<\/sup> testing may be considered in Rett syndrome patients with neurological deterioration that exceeds what would be expected from the underlying genetic condition alone.[\/vc_column_text][vc_custom_heading text=&#8221;Group 6: Adults with Unexplained Neuropsychiatric or Neurological Symptoms&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>FRAT<sup>\u00ae<\/sup> may also be relevant for adults presenting with:<\/p>\n<ul>\n<li><strong>Treatment-resistant depression<\/strong> or mood disorders<\/li>\n<li><strong>Unexplained neurological symptoms<\/strong> (cognitive decline, movement abnormalities)<\/li>\n<li><strong>Autoimmune conditions<\/strong> with neuropsychiatric features<\/li>\n<\/ul>\n<p>Case reports describe individuals whose lives were transformed by identifying FRAA positivity after years of ineffective psychiatric treatment. While large-scale studies in adult psychiatric populations are more limited, the mechanism is biologically plausible and the test is low-risk.<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;What FRAT<sup>\u00ae<\/sup> Does Not Tell You&#8221; el_id=&#8221;blog-scroll-point-2&#8243;][vc_column_text single_style=&#8221;&#8221;]Understanding the limitations is as important as knowing who to test.<\/p>\n<p><strong>A positive FRAT<sup>\u00ae<\/sup> does not confirm cerebral folate deficiency.<\/strong> The gold standard remains <strong>lumbar puncture with CSF 5-MTHF measurement.<\/strong> FRAT<sup>\u00ae<\/sup> identifies a mechanism (autoimmune interference with folate transport) but does not prove that this mechanism is causing a specific patient&#8217;s symptoms.<\/p>\n<p><strong>A negative FRAT does not completely rule out CFD.<\/strong> Other mechanisms can impair folate transport, and antibody titers can fluctuate over time. The presence of antibodies alone does not mandate treatment \u2014 clinical correlation is essential.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;The Treatment Connection: Why Testing Matters&#8221;][vc_column_text single_style=&#8221;&#8221;]The value of FRAT<sup>\u00ae<\/sup> testing lies in its potential to identify individuals who may benefit from reduced folates such as<strong> folinic acid (leucovorin) supplementation<\/strong> \u2014 a form of folate that can bypass the blocked receptor and enter the brain through alternative transport mechanisms such as the reduced folate carrier.<\/p>\n<p>Multiple studies have demonstrated clinical improvement with folinic acid in FRAA-positive individuals:<\/p>\n<ul>\n<li>In the original CFD cohort, oral folinic acid normalized CSF 5-MTHF and led to clinical improvement.<\/li>\n<li>In low-functioning autism with neurological deficits, folinic acid supplements led to normal CSF 5-MTHF and <strong>partial or complete clinical recovery after 12 months<\/strong>.<\/li>\n<li>In a 2024 ASD study, higher binding FRAA titers predicted greater treatment response to leucovorin.<\/li>\n<li>In treatment-resistant schizophrenia, folinic acid administration resulted in clinical improvement.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]The 2025 national attention on leucovorin for autism has brought this research into public view, but the scientific foundation has been building for over two decades.[\/vc_column_text][vc_custom_heading text=&#8221;A Framework for Decision-Making&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>FRAT<sup>\u00ae<\/sup> testing is most appropriate when <strong>all three<\/strong> of the following conditions are met:<\/p>\n<ol>\n<li><strong>Clinical suspicion<\/strong>: The individual has symptoms consistent with cerebral folate deficiency (developmental delay, regression, seizures, movement disorders, treatment-resistant neuropsychiatric symptoms)<\/li>\n<li><strong>Normal serum folate<\/strong>: Routine blood work shows adequate folate levels, creating a paradox with clinical presentation<\/li>\n<li><strong>Potential treatment implications<\/strong>: Identification of FRAA positivity would meaningfully alter management (e.g., consideration of reduced folate\/folinic acid therapy and dietary adjustments such as a dairy free diet)<\/li>\n<\/ol>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>Testing is <strong>not<\/strong> indicated for:<\/p>\n<ul>\n<li>Individuals without clinical symptoms suggestive of folate transport impairment<\/li>\n<li>As a substitute for comprehensive diagnostic evaluation of autism or other neurodevelopmental conditions<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_custom_heading text=&#8221;The Evolving Science&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>It is important to acknowledge that FRAT<sup>\u00ae<\/sup> testing and reduced folate\/ folinic acid treatment for FRAA-positive individuals remain areas of active investigation. A 2026 federal strategic planning document emphasized the need for <strong>assay harmonization, biomarker-defined clinical trials, and validated evidence<\/strong> before broad clinical or coverage recommendations can be made<a href=\"https:\/\/iacc.hhs.gov\/meetings\/iacc-meetings\/2026\/full-committee-meeting\/july\/IACC%20Strategic%20Plan%20Working%20Draft%20July%2017.pdf#46#13\">.<\/a><\/p>\n<p>The evidence base is strongest for:<\/p>\n<ul>\n<li>Infantile-onset cerebral folate deficiency<\/li>\n<li>FRAA-positive ASD with neurological deficits<\/li>\n<li>Neural tube defect risk in FRAA-positive women<\/li>\n<\/ul>\n<p>For other populations, the evidence is suggestive but less robust. Research, however, is increasing.<\/p>\n<p>[\/vc_column_text][vc_custom_heading text=&#8221;Final Thoughts&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>The FRAT<sup>\u00ae<\/sup> test addresses a fundamental question that traditional blood tests cannot answer: <strong>Is folate actually reaching the brain?<\/strong><\/p>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>For decades, patients with neurological deterioration and normal blood work fell through the cracks of conventional medicine. The discovery of folate receptor autoantibodies and the development of the FRAT<sup>\u00ae<\/sup> test represent a paradigm shift \u2014 from measuring what is in the blood to assessing whether it can get where it needs to go.<\/p>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>The individuals most likely to benefit are those whose clinical picture suggests a &#8220;starving brain&#8221; despite a well-nourished bloodstream. For these patients, FRAT<sup>\u00ae<\/sup> testing may open a door to targeted treatment that addresses the underlying mechanism rather than just the symptoms.<\/p>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>As with any specialized medical test, the decision to pursue FRAT<sup>\u00ae<\/sup> testing needs to be made in consultation with a qualified healthcare provider who can interpret results in the context of the full clinical picture and guide appropriate next steps.<\/p>\n<p>[\/vc_column_text][vc_custom_heading text=&#8221;References:&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<ol>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14711912\/#1\">https:\/\/pubmed.ncbi.nlm.nih.gov\/14711912\/#1<\/a><\/li>\n<li><strong>Levels of folate receptor autoantibodies in maternal and cord blood and risk of neural tube defects in a Chinese population.<\/strong><br \/>\n<a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Yang,%20Na%22\">Yang, Na<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Wang,%20Linlin%22\">Wang, Linlin<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Finnell,%20Richard%20H%22\">Finnell, Richard H<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Li,%20Zhiwen%22\">Li, Zhiwen<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Jin,%20Lei%22\">Jin, Lei<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Zhang,%20Le%22\">Zhang, Le<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Cabrera,%20Robert%20M%22\">Cabrera, Robert M<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Ye,%20Rongwei%22\">Ye, Rongwei<\/a>; <a href=\"https:\/\/pesquisa.bvsalud.org\/portal\/?lang=pt&amp;q=au:%22Ren,%20Aiguo%22\">Ren, Aiguo<\/a>.<\/li>\n<li><a href=\"http:\/\/portal.revistas.bvs.br\/pt\/journals\/?q=short_title:%22Birth%20Defects%20Res%20A%20Clin%20Mol%20Teratol%22\"><em><strong>Birth Defects Res A Clin Mol Teratol <\/strong><\/em><\/a>; 106(8): 685-95, 2016 Aug.<br \/>\nArticle em En | MEDLINE | ID: mdl-27166990<\/li>\n<li><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1096719214003114\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1096719214003114<\/a><\/li>\n<li><a href=\"https:\/\/orbi.uliege.be\/bitstream\/2268\/168813\/1\/Folate%20receptor%20autoantibodies%20and%20spinal%20fluid%205-methyltetrahydrofolate%20deficiency%20in%20Rett%20syndrome.pdf\">https:\/\/orbi.uliege.be\/bitstream\/2268\/168813\/1\/Folate%20receptor%20autoantibodies%20and%20spinal%20fluid%205-methyltetrahydrofolate%20deficiency%20in%20Rett%20syndrome.pdf<\/a><\/li>\n<\/ol>\n<ol start=\"6\">\n<li><a href=\"https:\/\/www.downstate.edu\/about\/office-of-the-president\/presidents-bulletin\/2025\/10-07\/04-research-on-folate-and-autism.html#1\">https:\/\/www.downstate.edu\/about\/office-of-the-president\/presidents-bulletin\/2025\/10-07\/04-research-on-folate-and-autism.html#1<\/a><\/li>\n<li><a href=\"https:\/\/iacc.hhs.gov\/meetings\/iacc-meetings\/2026\/full-committee-meeting\/july\/IACC%20Strategic%20Plan%20Working%20Draft%20July%2017.pdf#46#13\">https:\/\/iacc.hhs.gov\/meetings\/iacc-meetings\/2026\/full-committee-meeting\/july\/IACC%20Strategic%20Plan%20Working%20Draft%20July%2017.pdf#46#13<\/a><\/li>\n<li><a href=\"https:\/\/orbi.uliege.be\/bitstream\/2268\/168811\/1\/Folate%20receptor%20autoimmunity%20and%20cerebral%20folate%20deficiency%20in%20low-functioning%20autism%20with%20neurological%20deficits.pdf\">https:\/\/orbi.uliege.be\/bitstream\/2268\/168811\/1\/Folate%20receptor%20autoimmunity%20and%20cerebral%20folate%20deficiency%20in%20low-functioning%20autism%20with%20neurological%20deficits.pdf<\/a><\/li>\n<\/ol>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>What is the FRAT\u00ae test? Learn what it tests, its potential role in folate transport, limitations, and how parents can discuss testing with a pediatrician.<\/p>\n","protected":false},"author":4,"featured_media":7873,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70,83],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Who May Benefit from the FRAT\u00ae Test<\/title>\n<meta name=\"description\" content=\"Learn who may benefit from the FRAT\u00ae Test, including people with cerebral folate deficiency, autism with neurological symptoms, Rett syndrome, and related conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Who May Benefit from the FRAT\u00ae Test\" \/>\n<meta property=\"og:description\" content=\"Learn who may benefit from the FRAT\u00ae Test, including people with cerebral folate deficiency, autism with neurological symptoms, Rett syndrome, and related conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/\" \/>\n<meta property=\"og:site_name\" content=\"fratnow.com\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/autismfrat\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-19T13:00:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-19T05:26:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/09\/who-may-benefit-from-the-frat-test-blog-listing-image.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"730\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Steve Tsetsekos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Who May Benefit from the FRAT\u00ae Test\" \/>\n<meta name=\"twitter:description\" content=\"Learn who may benefit from the FRAT\u00ae Test, including people with cerebral folate deficiency, autism with neurological symptoms, Rett syndrome, and related conditions.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/09\/who-may-benefit-from-the-frat-test-blog-listing-image.webp\" \/>\n<meta name=\"twitter:creator\" content=\"@AutismFrat\" \/>\n<meta name=\"twitter:site\" content=\"@AutismFrat\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Tsetsekos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Who May Benefit from the FRAT\u00ae Test","description":"Learn who may benefit from the FRAT\u00ae Test, including people with cerebral folate deficiency, autism with neurological symptoms, Rett syndrome, and related conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/","og_locale":"en_US","og_type":"article","og_title":"Who May Benefit from the FRAT\u00ae Test","og_description":"Learn who may benefit from the FRAT\u00ae Test, including people with cerebral folate deficiency, autism with neurological symptoms, Rett syndrome, and related conditions.","og_url":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/","og_site_name":"fratnow.com","article_publisher":"https:\/\/www.facebook.com\/autismfrat","article_published_time":"2026-09-19T13:00:36+00:00","article_modified_time":"2026-09-19T05:26:12+00:00","og_image":[{"width":730,"height":400,"url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/09\/who-may-benefit-from-the-frat-test-blog-listing-image.webp","type":"image\/webp"}],"author":"Steve Tsetsekos","twitter_card":"summary_large_image","twitter_title":"Who May Benefit from the FRAT\u00ae Test","twitter_description":"Learn who may benefit from the FRAT\u00ae Test, including people with cerebral folate deficiency, autism with neurological symptoms, Rett syndrome, and related conditions.","twitter_image":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/09\/who-may-benefit-from-the-frat-test-blog-listing-image.webp","twitter_creator":"@AutismFrat","twitter_site":"@AutismFrat","twitter_misc":{"Written by":"Steve Tsetsekos","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","BlogPosting"],"@id":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/#article","isPartOf":{"@id":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/"},"author":{"name":"Steve Tsetsekos","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/d5e4020455f25cb3768f5eb9ad5e9f1c"},"headline":"Who May Benefit from the FRAT\u00ae Test","datePublished":"2026-09-19T13:00:36+00:00","dateModified":"2026-09-19T05:26:12+00:00","mainEntityOfPage":{"@id":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/"},"wordCount":2131,"commentCount":0,"publisher":{"@id":"https:\/\/autism.fratnow.com\/blog\/#organization"},"articleSection":["Neurodiversity &amp; Wellbeing","Patient\/Caregiver Education"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/","url":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/","name":"Who May Benefit from the FRAT\u00ae Test","isPartOf":{"@id":"https:\/\/autism.fratnow.com\/blog\/#website"},"datePublished":"2026-09-19T13:00:36+00:00","dateModified":"2026-09-19T05:26:12+00:00","description":"Learn who may benefit from the FRAT\u00ae Test, including people with cerebral folate deficiency, autism with neurological symptoms, Rett syndrome, and related conditions.","breadcrumb":{"@id":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/autism.fratnow.com\/blog\/who-may-benefit-from-the-frat-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/autism.fratnow.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Who May Benefit from the FRAT\u00ae Test"}]},{"@type":"WebSite","@id":"https:\/\/autism.fratnow.com\/blog\/#website","url":"https:\/\/autism.fratnow.com\/blog\/","name":"fratnow.com","description":"","publisher":{"@id":"https:\/\/autism.fratnow.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/autism.fratnow.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/autism.fratnow.com\/blog\/#organization","name":"fratnow.com","url":"https:\/\/autism.fratnow.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/08\/logo.png","contentUrl":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/08\/logo.png","width":194,"height":66,"caption":"fratnow.com"},"image":{"@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/autismfrat","https:\/\/twitter.com\/AutismFrat","https:\/\/www.linkedin.com\/company\/88011685\/admin\/","https:\/\/www.instagram.com\/fratautism\/"]},{"@type":"Person","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/d5e4020455f25cb3768f5eb9ad5e9f1c","name":"Steve Tsetsekos","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/09\/e6cec733-36d3-42ae-a0a7-986995164499_medium.jpg","contentUrl":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/09\/e6cec733-36d3-42ae-a0a7-986995164499_medium.jpg","caption":"Steve Tsetsekos"},"sameAs":["https:\/\/autism.fratnow.com\/blog\/"],"url":"https:\/\/autism.fratnow.com\/blog\/author\/steve-tsetsekos\/"}]}},"_links":{"self":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7872"}],"collection":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/comments?post=7872"}],"version-history":[{"count":2,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7872\/revisions"}],"predecessor-version":[{"id":7875,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7872\/revisions\/7875"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/media\/7873"}],"wp:attachment":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/media?parent=7872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/categories?post=7872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/tags?post=7872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}